Background: Argininemia is an autosomal recessive urea cycle disorder (UCD). Unlike other UCD, hyperammonemia is rarely seen. Patients usually present in childhood with neurological symptoms. Uncommon presentations like neonatal cholestasis or cirrhosis have been reported. Although transient elevations of liver transaminases and coagulopathy have been reported during hyperammonemia episodes, a permanent coagulopathy has never been reported. Methods: In this retrospective study, coagulation disturbances are examined in 6 argininemia patients. All of the patients were routinely followed up for hepatic involvement due to argininemia. Laboratory results, including liver transaminases, albumin, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and clotting factor levels, were assessed in all of the patients. Results: All of the patients had a prolonged PT and an increased INR, while none of the patients had a prolonged aPTT. Five patients had slightly elevated liver transaminases. A liver biopsy was performed in 1 patient but neither cirrhosis nor cholestasis was documented. Five of the 6 patients had low factor VII and factor IX levels, while other clotting factors were normal. Conclusions: Argininemia patients should be investigated for coagulation disorders even if there is no apparent liver dysfunction or major bleeding symptoms.
Introduction
Argininemia is an autosomal recessive disease caused by a defect in arginase 1 (ARG1), an enzyme involved in the urea cycle. Three urea cycle enzymes, i.e., N-acetylglutamate synthase, carbamoyl phosphate synthetase 1, and ornithine transcarbamylase (OTC), are located in mitochondria, while the latter 3 enzymes, i.e., argininosuccinic acid synthetase, argininosuccinic acid lyase, and ARG1, are expressed in the cytosol [1] . ARG1, as the final step of the urea cycle, catalyzes the conversion of arginine to urea that is excreted in urine, and ornithine that participates in the cycle. ARG1 deficiency (ARG1D, OMIM #207800) is a very rare disorder, with a reported estimated incidence rate between 1/365,000 and 1/2,000,000 [1] [2] [3] [4] .
Different from all of other urea cycle disorders (UCD), neonatal or early infantile onset disease with hyperammonemic decompensation is rarely seen in ARG1D [1, 2, 5] . Classic clinical manifestations of the disease are spastic paraparesis, mental retardation, failure to thrive, and episodic hyperammonemia, mostly starting in early childhood [2, 6] . Uncommon presentations of ARG1D with neonatal cholestasis or cirrhosis have been reported [7, 8, 9] . Transient elevations of liver transaminases and coagulopathy have been reported during episodes of hyperammonemia, but a permanent coagulopathy has never been reported [1, 2, 6] .
Here we present 6 ARG1D patients who were all affected by coagulation disturbances that were detected during routine investigations for hepatic involvement of argininemia.
Methods
All of the patients were followed up at the Pediatric Nutrition and Metabolic Disorders Clinic of the Cerrahpasa Medical Faculty in Istanbul, Turkey. Medical data were collected retrospectively from patients' charts. Data collection included: age at diagnosis, current age, gender, consanguinity, history of neonatal cholestasis, and major-minor bleeding history ( Table 1) .
The collected data included liver transaminases (alanine aminotransferase and aspartate aminotransferase), γ-glutamyl transferase, alkaline phosphatase, albumin, PT, INR, aPTT, and clotting factor levels. Clotting factor assays were performed as 1-stage clotting-based tests using commercial plasma deficient of the relevant factor on different coagulation analyzers (BCT, BCS of Dade-Behring/Siemens or CA-1500 of Sysmex) depending on the availability. Mutation analysis of the ARG1 gene was performed by standard Sanger sequencing of single exons with flanking intronic regions. The laboratory results and the ARG1 mutation analysis are shown in Table 2 .
Results
Six patients with argininemia were enrolled into this study. One patient was diagnosed by family screening following the diagnosis of an affected sibling (patient 2). The remaining patients were diagnosed via a selective metabolic workup for neuromotor retardation. All of the patients had severe psychomotor retardation with spastic diplegia at the time of diagnosis. Patient 3 was also diagnosed with type 1 hyperlipidemia, with plasma triglyceride values ranging between 999 and 2,100 mg/dL. Molecular analysis of the ARG1 gene was compatible with argininemia in 5 of the 6 patients, whereas patient 3 did not give consent for mutation analysis. All of the patients were routinely followed up for hepatic involvement due to ARG1D. Three patients (patients 1, 2, and 3) had minor bleeding findings (petechiae and ecchymosis) that were detected on routine physical examination, and 2 patients (patients 4 and 6) had abnormal laboratory findings noticed during preoperative testing. PT was prolonged and INR was increased, while aPTT was normal in all of the patients. Five patients had slightly elevated liver transaminases. Patient 4 had markedly elevated transaminases; a liver biopsy was performed but neither liver cirrhosis nor cholestasis was documented. Five of the 6 patients had low factor VII and factor IX levels, while other clotting factors were normal. Details of clinical characteristics and laboratory findings are summarized in Tables 1  and 2 . 
Discussion
Argininemia due to ARG1D is the least common UCD, along with N-acetyl-glutamate synthase and CPS deficiencies. Unlike other UCD, hyperammonemia episodes and neonatal presentations are uncommon in argininemia. The classical presentation of the disease is characterized by progressive neurologic impairment in early childhood after an apparently normal development. The exact mechanism of the central nervous system injury is, however, still not fully understood. Direct toxic effects of elevated arginine and arginine metabolites including guanido components and nitric oxide have been suggested to be responsible for neurotoxicity [10, 11] . Besides the neurologic involvement, extraneurological symptoms are also present and the liver is the main affected organ. Hepatic involvement in argininemia can vary from mild hepatocellular injury with transient elevations of liver transaminases to coagulation abnormalities and hepatic failure as in other UCD [7] [8] [9] 12] .
Here we present 6 patients with argininemia and coagulation disturbances. The coagulation abnormalities were detected during routine investigations for hepatic involvement of argininemia or before surgical procedures. All of our patients had mild to severe hepatic involvement with elevation of liver transaminases, and only 1 patient had mild hepatic fibrosis but no signs of hepatic failure were documented.
Data from the European registry of UCD show that highest frequency of liver disease is present in ASL and OTC deficiency among all UCD [13] . A recent study confirmed that neonatal histopathological changes in hepatic involvement of UCD are nonspecific, whereas older patients develop variable hepatic fibrosis and focal changes resembling glycogen storage disorder and cirrhosis [14] . The exact mechanism of liver injury in UCD is not known. It has been claimed that hyperammonemia can lead to a decrease in hepatic protein synthesis and especially to a reduction of coagulation factors, which are liver-derived proteins with a short plasma half-life [15] . According to this study, OTC-deficient patients were observed to have decreased factor VII and concomitantly increased INR during hyperammonemia episodes [15] . Although hyperammonemia is not a constant finding of argininemia, additional factors that have not been described yet might play a role in liver damage. A recent case report showed no correlation between the coagulopathy and plasma ammonia levels or with serum albumin levels, indicating the heterogeneous etiology of liver damage in OTC deficiency [16] . In this study, none of our patients had hyperammonemia accompanying the coagulation abnormalities. The coagulation abnormalities of our patients were per- manent, independently of the patient's metabolic status. Although coagulation abnormalities in urea cycle disorders during hyperamonemia episodes have been well described, plasma ammonia levels were found to be within the normal ranges at the time of blood sampling in all of the patients. As a result, coagulation abnormalities were not found to be associated with hyperammonemic episodes. Therefore, we suppose that coagulation abnormalities are not correlated with hyperammonemia and additional mechanisms should play role in these patients. Five of the 6 patients had low factor VII and factor IX levels, while other K vitamin-dependent factors like factors II and X were found to be normal. In order to rule out a vitamin K deficiency (factors VII and IX have the shortest half-lives among other vitamin K-dependent factors), parenteral vitamin K was attempted, with no improvement in coagulation parameters. Moreover, all of the patients had been on a low-protein diet with special formulas enriched with vitamin K 1 and none of them was nasogastrically/gastrically fed. Also, none of our patients was hospitalized for any medication before coagulation parameters were tested and none had history of chronic use of any medication that could interfere with vitamin K, such as antibiotics or anticonvulsants, except for patient 2, who had been using levetiracetam. Unfortunately, PIVKA-II levels were not measured for subclinical vitamin K deficiency. Levels of factor V, which is synthesized only in liver and plasma albumin, were found to be within the normal reference ranges in all of the patients. As individual laboratory values which were accepted to be reliable indicators of synthetic liver function were obtained simultaneously with coagulation parameters and were found to be normal, it was thought that the factor VII and factor IX deficiencies in our patients most probably did not result from the hepatic involvement of arginase deficiency [17, 18] . Interestingly, patient 5 had impaired coagulation parameters but no additional single-factor deficiency was identified. In addition, the existence of both factor VII and factor IX, which was observed in 5 of the 6 patients, excluded the congenital factor deficiencies in our ARG1D patients.
Despite the high incidence of coagulation disturbances, none of our patients had severe life-threating hemorrhages and only patients 1, 2, and 3 had minor bleeding problems such as petechia and ecchymosis detected during a routine physical examination. Petechia and ecchymosis are signs of primary hemorrhagic problems, indicating that platelet associated or vascular problems might be present. Platelet counts and platelet morphologies were normal in our patients. As major bleeding symptoms were not observed in our patient group, advanced laboratory analyses to evaluate platelet functions were not performed.
In conclusion, we report the frequent observation of coagulation abnormalities in a small cohort of ARG1D patients and recommend investigating these patients for coagulation status even in the absence of an apparent liver dysfunction or major bleeding symptoms. Due to the rarity of argininemia, it is difficult to study this disease in large patient cohorts, which would be required to find out whether coagulation factor deficiencies are common findings in ARG1D and whether they are related to hyperammonemia or other signs of liver dysfunction. Further studies with large sample sizes and longer follow-up periods should elucidate the relationship and pathophysiological mechanisms of coagulopathy and argininemia.
